Navigation Links
Kensey Nash to Participate in the Sidoti Thirteenth Annual New York Emerging Growth Institutional Investor Forum Conference
Date:3/13/2009

EXTON, Pa., March 13 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) is scheduled to present at the Sidoti Thirteenth Annual New York Emerging Growth Institutional Investor Forum at The Grand Hyatt in New York City on Tuesday, March 24, 2009.

Joseph W. Kaufmann, Kensey Nash's CEO, will deliver the Company's presentation, beginning at approximately 11:35 a.m. (ET). The presentation materials will be available on the company's website (www.kenseynash.com) beginning at 11:35 a.m. (ET) on Tuesday, March 24, 2009.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Kensey Nash Announces Appointment of Chief Financial Officer
2. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
3. Kensey Nash Announces Director Resignation
4. Kensey Nash Corporation Announces Its Second Quarter 2009 Earnings Release Date and Teleconference
5. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
6. Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2008 Earnings Release Date and Teleconference
7. Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance
8. Kensey Nash Announces the Closing on its Sale of the Endovascular Business to Spectranetics
9. Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference
10. Corrected Press Release: Kensey Nash to Present at the Bank of America 2008 Health Care Conference
11. Kensey Nash to Present at the Bank of America 2008 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino ... its network of more than 650 U.S.-based dealers. Rhino, a member of the Alamo ... flail mowers and cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers ...
(Date:3/29/2017)... ... ... pollen is the main cause of hay fever in the United States, with an estimated ... from May to July each year; with the worst time for sufferers being June and ... ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced ... retails normally at $29.97; for the remaining days of March, the price will be ... to a special price of just $10 (regular retail price $19.97). , The special ...
(Date:3/29/2017)... ... 2017 , ... Based on research from Guardian’s Fourth Annual ... trying to balance both short-term and long-term benefits demands. Are employers struggling ... complexity, companies are finding that the short-term strategies used to control costs, improve ...
(Date:3/29/2017)... ... March 29, 2017 , ... How big ... outpatient facilities, and who are the most active developers? , In the ... Healthcare Real Estate Insights (HREI) found that outpatient medical real estate development projects ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Novartis announced today ... has accepted the company,s Biologics License Application (BLA) ... an investigational chimeric antigen receptor T cell (CAR-T) ... young adult patients with B-cell acute lymphoblastic leukemia ... Novartis for a CAR-T. The priority review designation ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "South ... & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected to ... Untapped Proton Therapy Market for South Korea was ... Proton Therapy plays an important role in delivering comprehensive cancer care to ...
(Date:3/29/2017)... 29, 2017  Zynex (OTCQB: ZYXI), an innovative medical technology ... medical devices for pain management, stroke rehabilitation, cardiac monitoring ... the Company,s 2016 full-year investor webcast on Monday, April 3, ... The Company expects to file its 2016 full year ... ...
Breaking Medicine Technology: